🎗️ Abnormal Cervical Screening Management (ASCCP 2019)
Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
Abnormal Cervical Screening Management (ASCCP 2019)
Current screening result (HPV triage / co-test)
When to use
Risk-based management direction for abnormal cervical cancer screening (HPV/co-test) under ASCCP 2019.
How it works
Clinical action by immediate CIN3+ risk: ≥ 60% expedited treatment; 25–< 60% treatment or colposcopy; 4–< 25% colposcopy; < 4% set 1- or 3-year repeat or return to routine by 5-year risk.
Key points
- ASCCP 2019 shifted from result-based algorithms to 'equal management for equal risk' using immediate and 5-year CIN3+ risk.
- The precise risk depends on the current result combined with prior screening history — use the official ASCCP risk-estimator table/App for exact figures.
- HPV+ HSIL reaches a high immediate risk and favours expedited (excisional) treatment without colposcopy in non-pregnant adults.
- HPV+ AGC needs colposcopy + endocervical curettage, with endometrial sampling if ≥ 35 years or abnormal bleeding.
References
- Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.